DFDarcy Fehlings

Darcy Fehlings

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Darcy Fehlings has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Alan McComas

    McMaster University Medical Centre; Mary Chipman MSc, Biostatistician, Department of Public Health Sciences, University of Toronto

    2 shared publications
  • Boguslaw Wilk

    Children's Exercise and Nutrition Centre, Department of Pediatrics, Chedoke Hospital Division, McMaster University, Hamilton

    2 shared publications
  • Derek Stephens

    Department of Pediatrics, The Hospital for Sick Children, University of Toronto

    2 shared publications
  • Jiri Vajsar

    Division of Neurology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto

    2 shared publications
  • Kent Campbell

    Research methodologist/Statistician, Bloorview MacMillan Children's Centre, Department of Public Health Sciences, University of Toronto, Toronto, Canada

    2 shared publications
  • Oded Bar-Or

    Children's Exercise and Nutrition Centre, Department of Pediatrics, Chedoke Hospital Division, McMaster University, Hamilton, Ontario, Canada

    2 shared publications

Latest Publications

  • Anaerobic muscle performance of children after long-term recovery from Guillain-Barré syndrome

    by Darcy Fehlings, Jiri Vajsar, Boguslaw Wilk, Derek Stephens, Oded Bar-Or


  • Open Access

    The use of botulinum toxin in paediatric hypertonia

    by Darcy Fehlings

    Botulinum toxin has become an important component of standard practice in the management of children with hypertonia (spasticity or dystonia). Following intramuscular injection, the neurotoxin causes a reversible neuromuscular blockade, creating both muscle weakness and a reduction in tone. Frequent goals of botulinum toxin injection include improving motor function, promoting longitudinal muscle growth and decreasing painful muscle spasms. The neuromuscular blockade lasts for three to six months on average. The clinical effect may last longer and the safety profile is excellent. Strong evidence, including randomized trials, exists for the efficacy of botulinum toxin in the management of lower and upper extremity tone in children. Common clinical indications include spastic equinus (toe walking), hip subluxation, upper extremity spasticity associated with hemiplegia or quadriplegia, and multilevel leg muscle injections in children with spastic diplegia.


  • Anaerobic muscle performance of children after long-term recovery from Guillain-Barré syndrome

    by Darcy Fehlings, Jiri Vajsar, Boguslaw Wilk, Derek Stephens, Oded Bar-Or

    The aim of this study was to evaluate anaerobic muscle performance in children after long-term recovery from Guillain-Barré syndrome (GBS). Participants were recruited from all children and adolescents with GBS admitted to The Hospital for Sick Children, University of Toronto, Canada, between 1988 and 1995. We assessed 17 children (nine males, eight females; mean age at GBS diagnosis 7 years 11 months, SD 4 years 2 months; mean age at testing 14 years 1 month) more than two years after acute GBS. Participants completed the Wingate anaerobic test to evaluate mean and peak muscle power. For mean arm muscle power (mean 47.5% [SD 17.4%] of normal), only two participants were in the normal range. For mean leg muscle power (mean 83% [SD 28.3%] of normal), 15 participants were in the normal range. For arm peak power (mean 92.6% [SD 20.7%] of normal), 12 participants were in the normal range. For leg peak power (mean 116.3% of normal, SD 15.8%), all participants were in the normal range. Detailed manual muscle testing with the modified Medical Research Council scale was done on 34 muscle groups. Data were pooled to give a mean arm and leg muscle strength score (9.7, SD 0.30 and 9.4, SD 0.50 respectively). Pearson's correlations of muscle endurance with arm and leg strength were not significant. Children with GBS have excellent long-term recovery of peak muscle power. Muscle endurance, measured by mean muscle power, was normal in the legs but markedly low in the arms. Pediatric rehabilitation programs after GBS should specifically target endurance of arm muscles.


  • Evaluation of therapeutic electrical stimulation to improve muscle strength and function in children with types II/III spinal muscular atrophy

    by Darcy L Fehlings, Susan Kirsch, Alan McComas, Kent Campbell

    The study aimed to evaluate the effect of low‐intensity nighttime therapeutic electrical stimulation (TES) on arm strength and function in children with intermediate type spinal muscular atrophy (SMA). The design was a randomized controlled trial with a 6‐month baseline control period. Children were evaluated at baseline, 6, and 12 months. TES was applied from 6 to 12 months to the deltoid and biceps muscle, of a randomly selected arm with the opposite arm receiving a placebo stimulator. Thirteen individuals with SMA between 5 to 19 years of age were recruited into the study and eight completed the 12‐month assessment. No statistically significant differences between the treatment and control arm were found at baseline, 6, and 12 months for elbow flexors, or shoulder abductors on quantitative myometry or manual muscle testing. There was no significant change in excitable muscle mass assessed by M‐wave amplitudes, nor function on the Pediatric Evaluation of Disability Inventory (self‐care domain). Therefore, in this study there was no evidence that TES improved strength in children with SMA.


  • Evaluation of therapeutic electrical stimulation to improve muscle strength and function in children with types II/III spinal muscular atrophy

    by Darcy L Fehlings, Susan Kirsch, Alan McComas, Mary Chipman, Kent Campbell

    The study aimed to evaluate the effect of low-intensity night-time therapeutic electrical stimulation (TES) on arm strength and function in children with intermediate type spinal muscular atrophy (SMA). The design was a randomized controlled trial with a 6-month baseline control period. Children were evaluated at baseline, 6, and 12 months. TES was applied from 6 to 12 months to the deltoid and biceps muscle, of a randomly selected arm with the opposite arm receiving a placebo stimulator. Thirteen individuals with SMA between 5 to 19 years of age were recruited into the study and eight completed the 12-month assessment. No statistically significant differences between the treatment and control arm were found at baseline, 6, and 12 months for elbow flexors, or shoulder abductors on quantitative myometry or manual muscle testing. There was no significant change in excitable muscle mass assessed by M-wave amplitudes, nor function on the Pediatric Evaluation of Disability Inventory (self-care domain). Therefore, in this study there was no evidence that TES improved strength in children with SMA.


  • Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome

    by D. Fehlings, M. Rang, J. Glazier, C. Steele

    Evidence is increasing to suggest that botulinum toxin type A (BTX‐A) plays a role in the management of upper extremity spasticity in the paediatric population. However, little information is available on the clinical characteristics of the child that predict a response to this intervention. Our research group previously published a randomized controlled trial demonstrating that BTX‐A injection improves function of the upper extremity of children with spastic hemiplegia. In the present paper, we evaluate the child characteristics that predict a positive response to the BTX‐A injections in the randomized treatment group. The treatment group was divided into positive functional responders and nonresponders using a cut score of a change of 10 points on the Quality of Upper Extremity Skills Test (QUEST). A two‐way analysis of variance procedure was done comparing the following baseline characteristics: function as scored on the QUEST and the Pediatric Evaluation of Disability Inventory (PEDI) self‐care domain, grip strength, upper extremity spasticity and age. Grip strength was significantly higher in responders with a P‐value of 0.001. Young age approached significance with a P‐value of 0.05. Correlation of change scores on the QUEST with baseline characteristics in the treatment group yielded similar results. BTX‐A causes a reduction in spasticity and strength; we postulate that if the hand is weak initially, BTX‐A can decrease hand function. Two case reports are presented that highlight the importance of grip strength and age.